Last reviewed · How we verify
Betamethasone valerate 0.1%
Betamethasone valerate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Betamethasone valerate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis), Lichen planus, Lichen sclerosus.
At a glance
| Generic name | Betamethasone valerate 0.1% |
|---|---|
| Also known as | Betnovate cream, Topical betamethasone |
| Sponsor | GlaxoSmithKline |
| Drug class | Topical corticosteroid (Class III/IV potency) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Betamethasone valerate is a synthetic glucocorticoid that penetrates the skin and binds to intracellular glucocorticoid receptors, leading to suppression of inflammatory mediators, reduced vasodilation, and decreased immune cell infiltration. This results in reduced erythema, pruritus, and other inflammatory skin manifestations. The valerate ester formulation enhances skin penetration and potency compared to the parent betamethasone molecule.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)
- Lichen planus
- Lichen sclerosus
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
- Systemic corticosteroid absorption (with prolonged use or occlusion)
Key clinical trials
- Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis (NA)
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation (PHASE2, PHASE3)
- New Topical Treatment in Plaque Psoriasis (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients (PHASE4)
- Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis (PHASE1)
- Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia (PHASE3)
- Safety and Efficacy of CD10367 in Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betamethasone valerate 0.1% CI brief — competitive landscape report
- Betamethasone valerate 0.1% updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI